University of California

Alkermes, Inc.

Qwixel Therapeutics LLC

Columbia University

University of Miami

Origen Therapeutics, Inc.

Sherie L Morrison

Caiyun Xuan

Tzu-Hsuan Huang

Kham M Trinh

John M Timmerman

Alex Vasuthasawat

Phillip M Friden

David Stover

George Ayoub

Kham Trinh

Ruth M Starzyk

Eun-Chung Park

Robert Etches

Andrew Saxon

Ke Zhang

Mansoor S Mohammed

Manuel L Penichet

Joseph David Rosenblatt

Edward E Max

Seung-Uon Shin

Vernon T Oi

Patricia Young

Reiko King

John P McGrath

Jeffrey B Lyczak

Paul R Hinton

Esther Mikyung Yoo

M Josefina Coloma

Koteswara R Chintalacharuvu

Kote R Chintalacharuvu

Ramon Monta&ntilde;o

Alan G Wildeman

Letitia A Wims

Ramon Montaño

Lisan Peng

Jay Dela Cruz

In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-&#x3b1;) or to a mutant interferon alpha.

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-&#x3b1;) or to a mutant interferon alpha or to an interferon beta (IFN-&#x3b2;) or to a nutant interferon beta, or to an interferon gamma (IFN-&#x3b3;) or to a mutant interferon gamma.

Anti-CSPG4 fusions with interferon for the treatment of malignancy

Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-&#x3b1;) or interferon beta (IFN-&#x3b2;).

Targeted interferons demonstrate potent apoptotic and anti-tumor activities

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-&#x3b1;) or to a mutant interferon alpha or to an interferon beta (IFN-&#x3b2;) or to a mutant interferon beta, or to an interferon gamma (IFN-&#x3b3;) or to a mutant interferon gamma.

Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.

Antibody-endostatin fusion protein and its variants

Targeted interferons demonstrating potent apoptotic and anti-tumor activities

This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-&#x3b1;).

Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities

The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion proteins and innate and/or exogenous antigenic proteins are also provided.

Antibody fusion proteins: effective adjuvants of protein vaccination

Rh antibody hybrids for use in testing red blood cells for the presence of one or more Rh factors. The Rh hybrid antibody may also be used in therapeutic procedures which require the use of Rh antisera. The hybrid antibody includes an IgG anti-Rh antibody which has a polymeric tailpiece attached to the carboxy terminal end of each of the IgG antibody heavy chains. A hemagglutinin method is provided for Rh phenotyping in which agglutination of Rh-positive red blood cells is achieved in a one-step process involving addition of the hybrid Rh antisera to the red blood cells being tested.

Rh antibody

Growing community of inventors

Los Angeles, CA, United States of America

Sherie L Morrison